Two articles examined the safety and efficacy of AAV-mediated retinal pigment epithelium-specific protein 65 kDa (RPE65) gene replacement therapy in patients with inherited retinal dystrophies [50,51]. This evidence concerns the gene RPE65 and inherited retinal dystrophy.